Hologic (NASDAQ:HOLX) Issues FY25 Earnings Guidance

by · The Cerbat Gem

Hologic (NASDAQ:HOLX – Get Free Report) updated its FY25 earnings guidance on Monday. The company provided EPS guidance of $4.25-4.35 for the period, compared to the consensus EPS estimate of $4.33. The company issued revenue guidance of $4.15-4.20 billion, compared to the consensus revenue estimate of $4.21 billion. Hologic also updated its FY 2025 guidance to 4.250-4.350 EPS.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on HOLX shares. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. Stephens reissued an “overweight” rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Leerink Partners decreased their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Evercore ISI lifted their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research note on Tuesday, October 1st. Finally, StockNews.com cut shares of Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Hologic presently has an average rating of “Moderate Buy” and an average price target of $87.50.

Get Our Latest Report on HOLX

Hologic Stock Performance

Shares of Hologic stock traded up $1.39 on Monday, reaching $83.72. 3,241,693 shares of the company traded hands, compared to its average volume of 1,582,480. Hologic has a 52 week low of $66.93 and a 52 week high of $84.67. The company has a 50 day moving average of $80.99 and a 200 day moving average of $78.02. The firm has a market capitalization of $19.45 billion, a PE ratio of 28.48, a PEG ratio of 2.93 and a beta of 0.98. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32.

Insider Activity at Hologic

In other Hologic news, insider Brandon Schnittker sold 476 shares of the stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at $310,415.85. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.75% of the stock is currently owned by corporate insiders.

About Hologic

(Get Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Articles